New drug hope for Hard-to-Treat blood cancer
NCT ID NCT05503550
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program provides talquetamab, an experimental drug, to people with multiple myeloma that has returned or not responded to standard treatments. Talquetamab is given as an injection under the skin. The goal is to offer a potential treatment option for patients who have few alternatives.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Talquetamab (a drug given as a shot under the skin)
- What this could lead to
- If it works, this could offer a new treatment option for people with multiple myeloma that has come back or stopped responding to other therapies.
- What could go wrong
- This is a pre-approval access program, not a formal trial, so data on safety and effectiveness are limited. The drug may not work for everyone and could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can adding selinexor to standard therapy extend remission in Hard-to-Treat myeloma?
- Can a new drug combo outsmart Hard-to-Treat myeloma?
- Engineered immune cells take on Hard-to-Treat myeloma
- Home infusion for myeloma drug passes early safety check
- New hope for multiple myeloma: phase 3 trial launches
- New CAR T-Cell therapy targets Hard-to-Treat myeloma